Open-label, Multicenter, Single Arm, Phase III Study to Collect Additional Safety and Efficacy Data With Deferasirox Film-coated Tablets in Patients Completing Study CICL670F2201

Change From Baseline Creatinine Clearance (mL/Min) at Month 6 and Month 12

时间窗: Baseline, 6 and 12 months

The change from baseline at each time point is calculated only for subjects with a value at baseline and the particular time point. Post = Post baseline, Change = Post - Baseline

Change From Baseline Alanine Aminotransferase/Serum Glutamic Pyruvic Transaminase (ALT/SGPT) (U/L) at Month 6 and Month 12

时间窗: Baseline, 6 and 12 months

The change from baseline at each time point is calculated only for subjects with a value at baseline and the particular time point. Post = Post baseline, Change = Post - Baseline

Change From Baseline Aspartate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) (U/L) at Month 6 and Month 12

时间窗: Baseline, 6 and 12 months

The change from baseline at each time point is calculated only for subjects with a value at baseline and the particular time point. Post = Post baseline, Change = Post - Baseline

Change From Baseline Red Blood Cells (RBC) (10^12 Cells/L) at Month 6 and Month 12

时间窗: Baseline, 6 and 12 months

The change from baseline at each time point is calculated only for subjects with a value at baseline and the particular time point. Post = Post baseline, Change = Post - Baseline

Change From Baseline Platelets (10^9 Cells/L) at Month 6 and Month 12

时间窗: Baseline, 6 and 12 months

The change from baseline at each time point is calculated only for subjects with a value at baseline and the particular time point. Post = Post baseline, Change = Post - Baseline

Change From Baseline Serum Creatinine (Umol/L) at Month 6 and Month 12

时间窗: Baseline, 6 and 12 months

The change from baseline at each time point is calculated only for subjects with a value at baseline and the particular time point. Post = Post baseline, Change = Post - Baseline

Overview of Number of Participants With Adverse Events

时间窗: Baseline up to approximately 25 months

Numbers represent counts of participants within the categories. An adverse event (AE) was defined as treatment emergent if its onset date is on or after (≥) the first administration of study treatment within this study or events present prior to start of study treatment but increased in severity on or after (≥) the first administration of study treatment within this study but not later than 30 days after the last study treatment in this study

Change From Baseline White Blood Cells (WBC) (10^9 Cells/L) at Month 6 and Month 12

时间窗: Baseline, 6 and 12 months

The change from baseline at each time point is calculated only for subjects with a value at baseline and the particular time point. Post = Post baseline, Change = Post - Baseline